Navin Fluorine International (532504) Q4 24/25 earnings summary

Executive summary

• Achieved record annual revenue of ₹2,393.11 crores and strong profitability growth in FY25, with robust operational performance and strategic project execution.

• Expanded capabilities through strategic agreements with Chemours and Buss ChemTech AG, enhancing product offerings in advanced materials and high-purity chemicals.

• Maintained a strong order book with multi-year contracts and robust visibility for future growth, supported by new commercial projects and technology tie-ups.

• Board recommended a final dividend of ₹7 per share (350% of face value) for FY25, with interim dividend of ₹5 per share paid during the year.

• Board approved fund raising up to ₹750 crores via equity or convertible instruments, subject to approvals.

Financial highlights

• FY25 consolidated revenue was ₹2,393.11 crores, up 14% YoY; Q4FY25 revenue was ₹701 crores, up 16% YoY and sequentially.

• FY25 operating EBITDA was ₹534 crores (+34% YoY), margin at 22.7%; Q4FY25 EBITDA was ₹179 crores (+62% YoY), margin at 25.5%.

• FY25 profit after tax was ₹289 crores (+6.7% YoY); Q4FY25 PAT was ₹95 crores (+35% YoY).

• Operating cash flow for FY25 was ₹571 crores.

• Standalone revenue for FY25 was ₹1,742.35 crores; standalone PAT was ₹241.93 crores.

Outlook and guidance

• Margin guidance maintained at 25% for FY26, with a range of 23%-27% depending on market conditions.

• Strong order book and multi-year contracts support robust projections for CDMO and specialty chemicals into FY26 and beyond.

• New molecule launches and capacity expansions planned for FY26, including AHF plant commissioning by Q2 FY26 and cGMP-4 by Q3 FY26.

• CapEx budget for FY26 is ₹500-600 crores, supported by a strong balance sheet.

• Board approved fund raising to support future growth and expansion.